AstraZeneca and Bristol-Myers Squibb Company today announced that their marketing authorisation application for ONGLYZA (saxagliptin) received a positive opinion from the Committee for Medicinal Prod
read more » Discuss Add this link to...Bury Add to:
| Bookmarks
AstraZeneca and Bristol-Myers Squibb today announced that the US Food and Drug Administration (FDA) has approved ONGLYZA (saxagliptin) for the treatment of type 2 diabetes mellitus in adults. ONGLYZA
read more » Discuss Add this link to...Bury Add to:
| Bookmarks